TWI245075B - Recombinant MVA virus, and the use thereof - Google Patents

Recombinant MVA virus, and the use thereof Download PDF

Info

Publication number: TWI245075B
Authority: TW; Taiwan
Prior art keywords: mva; virus; scope; recombinant; genome
Prior art date: 1995-07-04

Application number

TW092116681A

Other languages

English (en)

Chinese (zh)

Other versions

TW200305646A (en

Inventor

Gerd Sutter

Marion Ohlmann

Volker Erfle

Original Assignee

Gsf Forschungszentrum Umwelt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-04

Filing date

1996-12-31

Publication date

2005-12-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI245075(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-12-31 Application filed by Gsf Forschungszentrum Umwelt filed Critical Gsf Forschungszentrum Umwelt

2003-11-01 Publication of TW200305646A publication Critical patent/TW200305646A/zh

2005-12-11 Application granted granted Critical

2005-12-11 Publication of TWI245075B publication Critical patent/TWI245075B/zh

Links

241001183012 Modified Vaccinia Ankara virus Species 0.000 title claims description 70
241000700605 Viruses Species 0.000 claims abstract description 196
108090000623 proteins and genes Proteins 0.000 claims abstract description 153
238000012217 deletion Methods 0.000 claims abstract description 54
230000037430 deletion Effects 0.000 claims abstract description 53
229960005486 vaccine Drugs 0.000 claims abstract description 47
239000000427 antigen Substances 0.000 claims abstract description 39
108091007433 antigens Proteins 0.000 claims abstract description 38
102000036639 antigens Human genes 0.000 claims abstract description 38
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
238000004519 manufacturing process Methods 0.000 claims abstract description 18
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
239000003814 drug Substances 0.000 claims abstract description 11
229920001184 polypeptide Polymers 0.000 claims abstract description 11
229940124597 therapeutic agent Drugs 0.000 claims abstract description 9
239000013603 viral vector Substances 0.000 claims abstract description 7
210000004027 cell Anatomy 0.000 claims description 114
238000000034 method Methods 0.000 claims description 78
239000013598 vector Substances 0.000 claims description 64
210000002706 plastid Anatomy 0.000 claims description 51
241000700618 Vaccinia virus Species 0.000 claims description 49
101710137500 T7 RNA polymerase Proteins 0.000 claims description 44
108020004414 DNA Proteins 0.000 claims description 41
108091028043 Nucleic acid sequence Proteins 0.000 claims description 29
230000014509 gene expression Effects 0.000 claims description 26
230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 22
101000606090 Homo sapiens Tyrosinase Proteins 0.000 claims description 21
208000015181 infectious disease Diseases 0.000 claims description 20
230000001177 retroviral effect Effects 0.000 claims description 17
241000725303 Human immunodeficiency virus Species 0.000 claims description 16
239000013604 expression vector Substances 0.000 claims description 15
241000271566 Aves Species 0.000 claims description 14
239000002245 particle Substances 0.000 claims description 14
210000002845 virion Anatomy 0.000 claims description 13
206010046865 Vaccinia virus infection Diseases 0.000 claims description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
239000003550 marker Substances 0.000 claims description 12
208000007089 vaccinia Diseases 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 11
238000011282 treatment Methods 0.000 claims description 10
241000282412 Homo Species 0.000 claims description 9
206010028980 Neoplasm Diseases 0.000 claims description 9
108700004028 nef Genes Proteins 0.000 claims description 9
230000001717 pathogenic effect Effects 0.000 claims description 9
241000712461 unidentified influenza virus Species 0.000 claims description 9
241000894006 Bacteria Species 0.000 claims description 8
208000006454 hepatitis Diseases 0.000 claims description 8
231100000283 hepatitis Toxicity 0.000 claims description 8
101150023385 nef gene Proteins 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
230000003612 virological effect Effects 0.000 claims description 8
208000030507 AIDS Diseases 0.000 claims description 7
108010084873 Human Immunodeficiency Virus nef Gene Products Proteins 0.000 claims description 7
201000001441 melanoma Diseases 0.000 claims description 7
241001465754 Metazoa Species 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 6
238000012258 culturing Methods 0.000 claims description 6
210000003527 eukaryotic cell Anatomy 0.000 claims description 6
210000005260 human cell Anatomy 0.000 claims description 6
244000005700 microbiome Species 0.000 claims description 6
244000045947 parasite Species 0.000 claims description 6
210000004881 tumor cell Anatomy 0.000 claims description 6
208000031886 HIV Infections Diseases 0.000 claims description 5
108700005077 Viral Genes Proteins 0.000 claims description 5
238000004113 cell culture Methods 0.000 claims description 5
238000003780 insertion Methods 0.000 claims description 5
230000037431 insertion Effects 0.000 claims description 5
238000004806 packaging method and process Methods 0.000 claims description 5
238000001890 transfection Methods 0.000 claims description 5
241001529453 unidentified herpesvirus Species 0.000 claims description 5
241000287828 Gallus gallus Species 0.000 claims description 4
208000037357 HIV infectious disease Diseases 0.000 claims description 4
241000223960 Plasmodium falciparum Species 0.000 claims description 4
210000002950 fibroblast Anatomy 0.000 claims description 4
230000006801 homologous recombination Effects 0.000 claims description 4
238000002744 homologous recombination Methods 0.000 claims description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
230000003053 immunization Effects 0.000 claims description 4
230000002441 reversible effect Effects 0.000 claims description 4
238000013518 transcription Methods 0.000 claims description 4
230000035897 transcription Effects 0.000 claims description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
230000008901 benefit Effects 0.000 claims description 3
-1 casein Amino acid Chemical class 0.000 claims description 3
230000001413 cellular effect Effects 0.000 claims description 3
238000000338 in vitro Methods 0.000 claims description 3
210000001161 mammalian embryo Anatomy 0.000 claims description 3
230000006798 recombination Effects 0.000 claims description 3
238000005215 recombination Methods 0.000 claims description 3
238000012546 transfer Methods 0.000 claims description 3
241001430294 unidentified retrovirus Species 0.000 claims description 3
241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
238000004043 dyeing Methods 0.000 claims description 2
238000011081 inoculation Methods 0.000 claims description 2
230000003834 intracellular effect Effects 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
206010072219 Mevalonic aciduria Diseases 0.000 claims 68
239000003937 drug carrier Substances 0.000 claims 3
241000894007 species Species 0.000 claims 2
241000283690 Bos taurus Species 0.000 claims 1
208000010711 Cattle disease Diseases 0.000 claims 1
244000241257 Cucumis melo Species 0.000 claims 1
235000015510 Cucumis melo subsp melo Nutrition 0.000 claims 1
208000010201 Exanthema Diseases 0.000 claims 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
101150087110 HCRT gene Proteins 0.000 claims 1
241000186359 Mycobacterium Species 0.000 claims 1
241000282320 Panthera leo Species 0.000 claims 1
235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
244000046052 Phaseolus vulgaris Species 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 claims 1
239000005018 casein Substances 0.000 claims 1
235000021240 caseins Nutrition 0.000 claims 1
201000005884 exanthem Diseases 0.000 claims 1
239000000835 fiber Substances 0.000 claims 1
206010022000 influenza Diseases 0.000 claims 1
238000002955 isolation Methods 0.000 claims 1
238000006116 polymerization reaction Methods 0.000 claims 1
206010037844 rash Diseases 0.000 claims 1
230000035807 sensation Effects 0.000 claims 1
235000015170 shellfish Nutrition 0.000 claims 1
239000013589 supplement Substances 0.000 claims 1
230000036344 tooth staining Effects 0.000 claims 1
230000009261 transgenic effect Effects 0.000 claims 1
239000003981 vehicle Substances 0.000 claims 1
238000001415 gene therapy Methods 0.000 abstract description 3
239000012634 fragment Substances 0.000 description 14
238000010276 construction Methods 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
238000000746 purification Methods 0.000 description 11
241000588724 Escherichia coli Species 0.000 description 9
239000002609 medium Substances 0.000 description 9
238000004458 analytical method Methods 0.000 description 8
238000002255 vaccination Methods 0.000 description 8
230000000694 effects Effects 0.000 description 7
108091008146 restriction endonucleases Proteins 0.000 description 7
108060008724 Tyrosinase Proteins 0.000 description 6
238000010586 diagram Methods 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
238000002105 Southern blotting Methods 0.000 description 5
241000700647 Variola virus Species 0.000 description 5
108010067390 Viral Proteins Proteins 0.000 description 5
230000002238 attenuated effect Effects 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
241000701867 Enterobacteria phage T7 Species 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
102000003425 Tyrosinase Human genes 0.000 description 4
108020005202 Viral DNA Proteins 0.000 description 4
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
229960005091 chloramphenicol Drugs 0.000 description 4
230000002458 infectious effect Effects 0.000 description 4
244000052769 pathogen Species 0.000 description 4
239000008188 pellet Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
239000002356 single layer Substances 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
241000712079 Measles morbillivirus Species 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
101150055766 cat gene Proteins 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
108700004025 env Genes Proteins 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
239000006166 lysate Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241000714177 Murine leukemia virus Species 0.000 description 2
101710192141 Protein Nef Proteins 0.000 description 2
108010008038 Synthetic Vaccines Proteins 0.000 description 2
230000003127 anti-melanomic effect Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
230000008029 eradication Effects 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
108700004026 gag Genes Proteins 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
229940115256 melanoma vaccine Drugs 0.000 description 2
238000001466 metabolic labeling Methods 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
108700004029 pol Genes Proteins 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000003531 protein hydrolysate Substances 0.000 description 2
229940124551 recombinant vaccine Drugs 0.000 description 2
238000012216 screening Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
241000713686 Bovine lentivirus group Species 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010005054 Deoxyribonuclease BamHI Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
101000856993 Homo sapiens Glutaminase liver isoform, mitochondrial Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241000700625 Poxviridae Species 0.000 description 1
208000005585 Poxviridae Infections Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
235000010724 Wisteria floribunda Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000005975 antitumor immune response Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000446 fuel Substances 0.000 description 1
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
102000051530 human GLS Human genes 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
210000002752 melanocyte Anatomy 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000011017 operating method Methods 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000009589 pathological growth Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000005180 public health Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
108700004027 tat Genes Proteins 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000006648 viral gene expression Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Manufacturing & Machinery (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

TW092116681A 1995-07-04 1996-12-31 Recombinant MVA virus, and the use thereof TWI245075B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK78295		1995-07-04

Publications (2)

Publication Number	Publication Date
TW200305646A TW200305646A (en)	2003-11-01
TWI245075B true TWI245075B (en)	2005-12-11

Family

ID=8097499

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TW092116681A TWI245075B (en)	1995-07-04	1996-12-31	Recombinant MVA virus, and the use thereof
TW085116379A TW575664B (en)	1995-07-04	1996-12-31	Recombinant MVA virus, and the use thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
TW085116379A TW575664B (en)	1995-07-04	1996-12-31	Recombinant MVA virus, and the use thereof

Country Status (26)

Country	Link
US (6)	US6440422B1 (2)
EP (3)	EP0836648B1 (2)
JP (3)	JP4312260B2 (2)
KR (1)	KR19990028617A (2)
CN (3)	CN1782071A (2)
AT (3)	ATE304058T1 (2)
AU (1)	AU721735B2 (2)
BR (1)	BR9609303B8 (2)
CA (3)	CA2225278C (2)
CZ (1)	CZ292460B6 (2)
DE (3)	DE69635172T2 (2)
DK (3)	DK1312679T3 (2)
EE (3)	EE04199B1 (2)
ES (3)	ES2249648T3 (2)
HU (2)	HU229261B1 (2)
IL (5)	IL122120A (2)
MX (1)	MX9800025A (2)
NO (1)	NO322476B1 (2)
NZ (1)	NZ313597A (2)
PL (1)	PL186857B1 (2)
PT (1)	PT836648E (2)
RU (1)	RU2198217C2 (2)
SI (3)	SI1312679T1 (2)
TW (2)	TWI245075B (2)
UA (3)	UA68327C2 (2)
WO (1)	WO1997002355A1 (2)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA68327C2 (en) *	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) *	1996-07-30	2006-10-10	Transgene S.A.	Pharmaceutical composition for treating papillomavirus tumors and infection
EP0951555A2 (en) *	1996-09-24	1999-10-27	Bavarian Nordic Research Institute A/S	Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
MY119381A (en) *	1996-12-24	2005-05-31	Gsf Forschungszentrum Umwelt	Recombinant mva virus, and the use thereof
US6969609B1 (en) *	1998-12-09	2005-11-29	The United States Of America As Represented By The Department Of Health And Human Serivces	Recombinant vector expressing multiple costimulatory molecules and uses thereof
FR2784997A1 (fr) *	1998-10-22	2000-04-28	Transgene Sa	Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
US20040265324A1 (en) *	1999-03-23	2004-12-30	Cardosa Mary Jane	Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
DE60040662D1 (de) *	1999-05-28	2008-12-11	Helmholtz Zentrum Muenchen	Vektor zur integration von heterologen sequenzen in poxvirusgenomen
US20150231227A1 (en) *	2000-03-02	2015-08-20	Emory University	Compositions and methods for generating an immune response
RU2280075C2 (ru)	2000-03-14	2006-07-20	Бавариан Нордик А/С	Измененный штамм модифицированного вируса коровьей оспы ankara (mva)
RU2217162C2 (ru) *	2000-04-10	2003-11-27	Государственный научный центр вирусологии и биотехнологии "Вектор"	Вакцина против вирусных инфекций
DE10042598A1 (de) *	2000-08-30	2002-03-28	Gsf Forschungszentrum Umwelt	Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
WO2002031168A2 (en) *	2000-10-10	2002-04-18	Genstar Therapeutics	Minimal adenoviral vector and recombinant vaccines based thereon
CN101676389A (zh)	2000-11-23	2010-03-24	巴法里安诺迪克有限公司	改良安卡拉痘苗病毒变体
US7445924B2 (en)	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
US7628980B2 (en)	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7740863B2 (en)	2001-04-06	2010-06-22	Merial	Recombinant vaccine against West Nile Virus
DE10143490C2 (de) *	2001-09-05	2003-12-11	Gsf Forschungszentrum Umwelt	Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
DE10144664B4 (de) *	2001-09-11	2005-06-09	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
AU2002356690B2 (en)	2001-12-04	2008-07-24	Bavarian Nordic A/S	Flavivirus NS1 subunit vaccine
US7056723B2 (en) *	2001-12-20	2006-06-06	Bavarian Nordic A/S	Method for the recovery and purification of poxviruses from infected cells
DK1420822T4 (en) †	2002-04-19	2017-10-09	Bavarian Nordic As	Modified vaccinia virus Ankara for vaccination of newborns
PL218318B1 (pl)	2002-05-16	2014-11-28	Bavarian Nordic As	Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
CA2481783A1 (en) *	2002-05-16	2003-11-27	Bavarian Nordic A/S	Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
US7501127B2 (en)	2002-05-16	2009-03-10	Bavarian Nordic A/S	Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003264144C1 (en)	2002-09-05	2009-12-17	Bavarian Nordic A/S	Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
DE10249390A1 (de) *	2002-10-23	2004-05-13	Ruprecht-Karls-Universität Heidelberg	Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
AU2003293675B2 (en)	2002-11-25	2009-04-23	Bavarian Nordic A/S	Recombinant poxvirus comprising at least two cowpox ATI promoters
DE602004015418D1 (de) *	2003-02-18	2008-09-11	Helmholtz Zentrum Muenchen	Rekombinantes mva und verfahren zur erzeugung davon
EP1601333B1 (en) *	2003-02-20	2013-01-23	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services	Novel insertion sites in pox vectors
US7731974B2 (en) *	2003-03-27	2010-06-08	Ottawa Hospital Research Institute	Mutant vesicular stomatitis viruses and uses thereof
AU2004223808B2 (en)	2003-03-27	2009-03-26	Ottawa Health Research Institute	Mutant vesicular stomatitis viruses and use thereof
US7163685B2 (en) *	2003-04-16	2007-01-16	City Of Hope	Human cytomegalovirus antigens expressed in MVA and methods of use
GB2402391A (en) *	2003-06-04	2004-12-08	Oxxon Pharmaccines Ltd	Fowlpox recombinant genome
DE602004031681D1 (de)	2003-07-21	2011-04-14	Transgene Sa	Multifunktionelle Cytokine
US20100189747A1 (en) *	2003-07-31	2010-07-29	Raymond Weinstein	Compositions and methods for treating or preventing hiv infection
EP1518932A1 (en)	2003-09-29	2005-03-30	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	Modified vaccinia virus Ankara (MVA) mutant and use thereof
DE602004009743T2 (de) *	2003-11-24	2008-08-28	Bavarian Nordic A/S	Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
WO2005054451A1 (ja)	2003-12-05	2005-06-16	Hokkaido Technology Licensing Office Co., Ltd.	高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター
EP1683870A1 (en) *	2005-01-24	2006-07-26	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	Vaccines based on the use of MVA
US20090269365A1 (en) *	2005-04-20	2009-10-29	University Of Washington	Immunogenic vaccinia peptides and methods of using same
EP2023954B1 (en) *	2006-05-19	2013-07-17	Sanofi Pasteur, Inc.	Immunological composition
ES2611975T3 (es) *	2006-06-20	2017-05-11	Transgene S.A.	Procedimiento para producir poxvirus y composiciones de poxvirus
US7972605B2 (en) *	2006-09-08	2011-07-05	Duke University	Modified vaccinia ankara virus vaccine
CN102026645B (zh)	2006-09-15	2016-01-27	渥太华医院研究机构	溶瘤弹状病毒
EP2073837B1 (en)	2006-10-06	2014-06-25	Bavarian Nordic Inc.	Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer
US20080241139A1 (en) *	2006-10-31	2008-10-02	Regents Of The University Of Colorado	Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
US8557764B2 (en) *	2007-01-26	2013-10-15	The Regents Of The University Of Colorado, A Body Corporate	Methods of modulating immune function
JP2010526528A (ja)	2007-05-03	2010-08-05	メディツィニーチェウニベルシタットインスブルック	補体因子ｈ由来ショートコンセンサスリピート−抗体構築物
US8003364B2 (en)	2007-05-14	2011-08-23	Bavarian Nordic A/S	Purification of vaccinia viruses using hydrophobic interaction chromatography
US8012738B2 (en) *	2007-05-14	2011-09-06	Bavarian Nordic A/S	Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003363B2 (en)	2007-05-14	2011-08-23	Bavarian Nordic A/S	Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US20100285050A1 (en) *	2007-10-05	2010-11-11	Isis Innovation Limited	Compositions and Methods
BRPI0800485B8 (pt) *	2008-01-17	2021-05-25	Univ Minas Gerais	vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
EP2240573A4 (en)	2008-02-12	2011-08-31	Sanofi Pasteur Ltd	METHODS OF USING ION EXCHANGE CHROMATOGRAPHY AND DIFFUSION EXCLUSION CHROMATOGRAPHY FOR PURIFYING POXVIRUS
US20110052627A1 (en) *	2008-06-20	2011-03-03	Paul Chaplin	Recombinant modified vaccinia virus measles vaccine
US8691502B2 (en)	2008-10-31	2014-04-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2010127115A1 (en)	2009-04-30	2010-11-04	Centre Hospitalier Universitaire Vaudois Lausanne (Chuv)	Modified immunization vectors
BR112012002628B1 (pt)	2009-08-07	2021-09-08	Transgene Sa	Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
EP2501405A4 (en) *	2009-11-20	2013-12-04	Inviragen Inc	COMPOSITION, METHOD, AND USES OF POX VIRUS ELEMENTS IN VACCINATE CONSTRUCTS
US9005632B2 (en)	2009-11-20	2015-04-14	Takeda Vaccines, Inc.	Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
WO2011119920A2 (en)	2010-03-25	2011-09-29	Oregon Health & Science University	Cmv glycoproteins and recombinant vectors
GB201006405D0 (en) *	2010-04-16	2010-06-02	Isis Innovation	Poxvirus expression system
US20110262965A1 (en) *	2010-04-23	2011-10-27	Life Technologies Corporation	Cell culture medium comprising small peptides
US20140093556A1 (en)	2011-01-28	2014-04-03	Sanofi Pasteur Sa	Immunological Compositions Against HIV
WO2012151272A2 (en)	2011-05-02	2012-11-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
SMT201800284T1 (it)	2011-06-10	2018-07-17	Univ Oregon Health & Science	Glicoproteine cmv e vettori ricombinanti
ES2813413T3 (es) *	2011-08-05	2021-03-23	Sillajen Biotherapeutics Inc	Métodos y composiciones para la producción de virus vaccina
EP2568289A3 (en)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2013046034A2 (en) *	2011-09-26	2013-04-04	Theravectys	Use of non-subtype b gag proteins for lentiviral packaging
EP2586461A1 (en)	2011-10-27	2013-05-01	Christopher L. Parks	Viral particles derived from an enveloped virus
DK2788021T3 (en)	2011-12-09	2017-04-10	Bavarian Nordic As	POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
EP2620446A1 (en)	2012-01-27	2013-07-31	Laboratorios Del Dr. Esteve, S.A.	Immunogens for HIV vaccination
ES2631608T3 (es)	2012-06-27	2017-09-01	International Aids Vaccine Initiative	Variante de la glicoproteína Env del VIH-1
WO2014009433A1 (en)	2012-07-10	2014-01-16	Transgene Sa	Mycobacterium resuscitation promoting factor for use as adjuvant
WO2014009438A2 (en)	2012-07-10	2014-01-16	Transgene Sa	Mycobacterial antigen vaccine
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
EP3587455A1 (en)	2012-10-23	2020-01-01	Emory University	Gm-csf and il-4 conjugates, compositions, and methods related thereto
US20140286981A1 (en)	2013-03-14	2014-09-25	Wisconsin Alumni Research Foundation	Broadly reactive mosaic peptide for influenza vaccine
DE102013004595A1 (de)	2013-03-15	2014-09-18	Emergent Product Development Germany Gmbh	RSV-Impfstoffe
EP2848937A1 (en)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
US10765731B2 (en)	2014-01-09	2020-09-08	Transgene Sa	Fusion of heterooligomeric mycobacterial antigens
GB201412494D0 (en) *	2014-07-14	2014-08-27	Ospedale San Raffaele And Fond Telethon	Vector production
HUE053585T2 (hu)	2014-09-26	2021-07-28	Beth Israel Deaconess Medical Ct Inc	Eljárások és készítmények humán immundeficiencia vírus fertõzés elleni védõ immunválasz indukálására
US11701418B2 (en)	2015-01-12	2023-07-18	Geovax, Inc.	Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)
ES3011733T3 (en)	2015-02-13	2025-04-08	Transgene	Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en)	2015-02-20	2016-08-25	Transgene Sa	Combination product with autophagy modulator
US10174292B2 (en)	2015-03-20	2019-01-08	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en)	2015-03-23	2018-04-03	International Aids Vaccine Initiative	Soluble HIV-1 envelope glycoprotein trimers
PL3390430T3 (pl)	2015-12-15	2020-03-31	Janssen Vaccines & Prevention B.V.	Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
CA3011014A1 (en)	2016-01-08	2017-07-13	Geovax, Inc.	Compositions and methods for generating an immune response to a tumor associated antigen
WO2017136419A1 (en)	2016-02-03	2017-08-10	Geovax Inc.	Compositions and methods for generating an immune response to a flavivirus
US10736962B2 (en) *	2016-02-25	2020-08-11	Memorial Sloan Kettering Cancer Center	Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
EP3452081A1 (en)	2016-05-04	2019-03-13	Transgene SA	Combination therapy with cpg tlr9 ligand
KR102389489B1 (ko)	2016-06-16	2022-04-22	얀센 백신스 앤드 프리벤션 비.브이.	Hiv 백신 제형
US10307477B2 (en)	2016-09-02	2019-06-04	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
SG10202001956UA (en)	2016-09-15	2020-04-29	Janssen Vaccines & Prevention Bv	Trimer stabilizing hiv envelope protein mutations
EP3522920A2 (en)	2016-10-10	2019-08-14	Transgene SA	Immunotherapeutic product and mdsc modulator combination therapy
BR112019026126A2 (pt)	2017-06-15	2020-06-30	Janssen Vaccines & Prevention B.V.	vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
JP7334124B2 (ja)	2017-06-21	2023-08-28	トランジェーヌ	個別化ワクチン
EP3655032A1 (en)	2017-07-19	2020-05-27	Janssen Vaccines & Prevention B.V.	Trimer stabilizing hiv envelope protein mutations
US20190022212A1 (en)	2017-07-21	2019-01-24	Beth Israel Deaconess Medical Center, Inc.	Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en)	2017-09-18	2019-03-21	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11311612B2 (en)	2017-09-19	2022-04-26	Geovax, Inc.	Compositions and methods for generating an immune response to treat or prevent malaria
JP7551496B2 (ja)	2017-10-31	2024-09-17	カリヴィルイムノセラピューティクス，インコーポレイテッド	全身送達のためのプラットフォーム腫瘍溶解性ベクター
JP7320601B2 (ja)	2018-09-11	2023-08-03	上▲海▼市公共▲衛▼生▲臨▼床中心	広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
TW202110476A (zh)	2019-05-22	2021-03-16	荷蘭商傑森疫苗防護公司	於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
KR20220011685A (ko)	2019-05-22	2022-01-28	길리애드 사이언시즈, 인코포레이티드	Tlr7 조절 화합물과 hiv 백신의 조합
CN114901297A (zh) *	2019-10-16	2022-08-12	卡利威尔免疫治疗公司	用于原位产生逆转录病毒的生产者病毒
EP4058058A1 (en)	2019-11-14	2022-09-21	Aelix Therapeutics S.L.	Dosage regimens for vaccines
EP3842065A1 (en)	2019-12-23	2021-06-30	Transgene	Process for designing a recombinant poxvirus for a therapeutic vaccine
WO2021260065A1 (en)	2020-06-24	2021-12-30	Consejo Superior De Investigaciones Científicas (Csic)	Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP3928789A1 (en)	2020-06-24	2021-12-29	Consejo Superior de Investigaciones Científicas (CSIC)	Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
PE20231175A1 (es)	2020-11-19	2023-08-01	Kalivir Immunotherapeutics Inc	Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL316712B2 (en)	2021-04-30	2025-12-01	Kalivir Immunotherapeutics Inc	Oncolytic viruses for modified mhc expression
EP4108257A1 (en)	2021-06-23	2022-12-28	Consejo Superior De Investigaciones Científicas	Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
WO2022269003A1 (en)	2021-06-23	2022-12-29	Consejo Superior De Investigaciones Cientificas	MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
WO2023077147A2 (en)	2021-11-01	2023-05-04	Pellis Therapeutics, Inc.	T-cell vaccines for patients with reduced humoral immunity
WO2023213764A1 (en)	2022-05-02	2023-11-09	Transgene	Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en)	2022-05-02	2023-11-09	Transgene	Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
US20230364227A1 (en)	2022-05-12	2023-11-16	Pellis Therapeutics, Inc.	Poxvirus adjuvant for t-cell vaccination
EP4316514A1 (en)	2022-08-03	2024-02-07	Consejo Superior de Investigaciones Científicas (CSIC)	Mva-based vectors and their use as vaccine against sars-cov-2
AU2024241503A1 (en)	2023-03-17	2025-08-14	Albert-Ludwigs-Universität Freiburg	Hbv antigen formulation for treating hepatitis b
WO2025172435A1 (en)	2024-02-13	2025-08-21	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Hbv antigen formulation for treating hepatitis b
WO2026041811A1 (en)	2024-08-23	2026-02-26	Transgene	Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE787901A (fr)	1971-09-11	1972-12-18	Freistaat Bayern Represente Pa	Vaccin antivariolique
JPH0795954B2 (ja)	1982-11-30	1995-10-18	アメリカ合衆国	外来性遺伝子発現のためのポックスウイルス組換え体の製造方法
US5679511A (en) *	1986-10-06	1997-10-21	Donald Guthrie Foundation For Medical Research, Inc.	CDNA clones for a regulatory protein in the melanin-production pathway
CA1341245C (en) *	1988-01-12	2001-06-05	F. Hoffmann-La Roche Ag	Recombinant vaccinia virus mva
US5221610A (en) *	1988-05-26	1993-06-22	Institut Pasteur	Diagnostic method and composition for early detection of HIV infection
CN1042564A (zh) *	1988-11-11	1990-05-30	中国科学院上海生物化学研究所	乙肝疫苗的制备方法及其制品
JPH03271233A (ja) *	1990-03-19	1991-12-03	Inst Pasteur	ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
JPH07501052A (ja) *	1991-10-28	1995-02-02	インスティチュート・パスツール	ウイルスエンベロープタンパク質と糖タンパク質の中和エピトープに相当するペプチドとの間の相乗作用によるウイルス感染に対する防御の誘発
ES2151544T3 (es) *	1992-12-22	2001-01-01	Ludwig Inst Cancer Res	Metodos para la deteccion y el tratamiento de individuos con celulas anormales que expresan antigenos peptidos hla-a2/tirosinasa.
US5620886A (en) *	1993-03-18	1997-04-15	Ludwig Institute For Cancer Research	Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
AU685521B2 (en) *	1993-10-19	1998-01-22	Ajinomoto Co., Inc.	Peptide capable of inducing immune response against HIV and aids preventive or remedy containing the peptide
US5676950A (en) *	1994-10-28	1997-10-14	University Of Florida	Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) *	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

1996
- 1996-03-07 UA UA97126424A patent/UA68327C2/uk unknown
- 1996-07-03 EE EE9700344A patent/EE04199B1/xx unknown
- 1996-07-03 PL PL96324347A patent/PL186857B1/pl unknown
- 1996-07-03 SI SI9630719T patent/SI1312679T1/sl unknown
- 1996-07-03 HU HU0402350A patent/HU229261B1/hu unknown
- 1996-07-03 DK DK03001379T patent/DK1312679T3/da active
- 1996-07-03 IL IL12212096A patent/IL122120A/xx not_active IP Right Cessation
- 1996-07-03 RU RU98101904/13A patent/RU2198217C2/ru active
- 1996-07-03 CA CA002225278A patent/CA2225278C/en not_active Expired - Lifetime
- 1996-07-03 CN CNA2005101248556A patent/CN1782071A/zh active Pending
- 1996-07-03 DK DK03001378T patent/DK1312678T3/da active
- 1996-07-03 EP EP96925654A patent/EP0836648B1/en not_active Expired - Lifetime
- 1996-07-03 DE DE69635172T patent/DE69635172T2/de not_active Expired - Lifetime
- 1996-07-03 CA CA2596274A patent/CA2596274C/en not_active Expired - Lifetime
- 1996-07-03 ES ES03001379T patent/ES2249648T3/es not_active Expired - Lifetime
- 1996-07-03 PT PT96925654T patent/PT836648E/pt unknown
- 1996-07-03 SI SI9630623T patent/SI0836648T1/xx unknown
- 1996-07-03 EP EP03001378A patent/EP1312678B1/en not_active Expired - Lifetime
- 1996-07-03 ES ES03001378T patent/ES2249647T3/es not_active Expired - Lifetime
- 1996-07-03 EE EEP200300331A patent/EE05138B1/xx unknown
- 1996-07-03 CN CNB961952547A patent/CN1154742C/zh not_active Expired - Lifetime
- 1996-07-03 DK DK96925654T patent/DK0836648T3/da active
- 1996-07-03 CZ CZ19974241A patent/CZ292460B6/cs not_active IP Right Cessation
- 1996-07-03 BR BRPI9609303-0B8A patent/BR9609303B8/pt active IP Right Grant
- 1996-07-03 JP JP50482497A patent/JP4312260B2/ja not_active Expired - Lifetime
- 1996-07-03 KR KR1019970709939A patent/KR19990028617A/ko not_active Ceased
- 1996-07-03 CA CA2608864A patent/CA2608864C/en not_active Expired - Lifetime
- 1996-07-03 MX MX9800025A patent/MX9800025A/es unknown
- 1996-07-03 EE EEP200300332A patent/EE04753B1/xx unknown
- 1996-07-03 ES ES96925654T patent/ES2199294T3/es not_active Expired - Lifetime
- 1996-07-03 DE DE69635173T patent/DE69635173T2/de not_active Expired - Lifetime
- 1996-07-03 UA UA20031212890A patent/UA75410C2/uk unknown
- 1996-07-03 AU AU66110/96A patent/AU721735B2/en not_active Expired
- 1996-07-03 SI SI9630718T patent/SI1312678T1/sl unknown
- 1996-07-03 WO PCT/EP1996/002926 patent/WO1997002355A1/en not_active Ceased
- 1996-07-03 AT AT03001379T patent/ATE304058T1/de active
- 1996-07-03 NZ NZ313597A patent/NZ313597A/xx not_active IP Right Cessation
- 1996-07-03 UA UA20031212892A patent/UA75411C2/uk unknown
- 1996-07-03 EP EP03001379A patent/EP1312679B8/en not_active Expired - Lifetime
- 1996-07-03 AT AT03001378T patent/ATE304057T1/de active
- 1996-07-03 CN CN2004100367144A patent/CN1554764B/zh not_active Expired - Lifetime
- 1996-07-03 AT AT96925654T patent/ATE239796T1/de active
- 1996-07-03 DE DE69628011T patent/DE69628011T2/de not_active Expired - Lifetime
- 1996-07-03 HU HU9802217A patent/HU224061B1/hu active IP Right Grant
- 1996-12-31 TW TW092116681A patent/TWI245075B/zh not_active IP Right Cessation
- 1996-12-31 TW TW085116379A patent/TW575664B/zh not_active IP Right Cessation
1998
- 1998-01-02 NO NO19980026A patent/NO322476B1/no not_active IP Right Cessation
- 1998-01-02 US US09/002,443 patent/US6440422B1/en not_active Expired - Lifetime
2002
- 2002-05-15 US US10/147,284 patent/US7198934B2/en not_active Expired - Fee Related
2004
- 2004-09-28 IL IL164318A patent/IL164318A/en not_active IP Right Cessation
2006
- 2006-09-19 US US11/523,030 patent/US20070071770A1/en not_active Abandoned
- 2006-09-19 US US11/522,889 patent/US8153138B2/en not_active Expired - Fee Related
- 2006-09-19 US US11/523,004 patent/US20070071769A1/en not_active Abandoned
2007
- 2007-03-12 JP JP2007062630A patent/JP4764366B2/ja not_active Expired - Lifetime
- 2007-03-12 JP JP2007062631A patent/JP4764367B2/ja not_active Expired - Lifetime
2009
- 2009-12-01 IL IL202448A patent/IL202448A0/en unknown
2010
- 2010-06-14 US US12/814,602 patent/US8197825B2/en not_active Expired - Fee Related
2011
- 2011-05-17 IL IL212933A patent/IL212933A0/en unknown
2012
- 2012-05-02 IL IL219528A patent/IL219528A0/en unknown

Also Published As

Publication number	Publication date
HUP9802217A2 (hu)	1999-01-28
BR9609303B8 (pt)	2014-05-06
ATE304057T1 (de)	2005-09-15
HU229261B1 (en)	2013-10-28
DK1312678T3 (da)	2005-12-19
EP1312678A1 (en)	2003-05-21
ES2249647T3 (es)	2006-04-01
JP2007244382A (ja)	2007-09-27
IL212933A0 (en)	2011-07-31
EE200300331A (et)	2003-10-15
DE69635173T2 (de)	2006-07-13
CN1554764A (zh)	2004-12-15
IL122120A (en)	2005-07-25
CA2225278C (en)	2009-01-27
EP1312678B1 (en)	2005-09-07
US6440422B1 (en)	2002-08-27
ES2199294T3 (es)	2004-02-16
DK0836648T3 (da)	2003-08-25
ATE239796T1 (de)	2003-05-15
TW200305646A (en)	2003-11-01
ATE304058T1 (de)	2005-09-15
SI1312678T1 (sl)	2006-02-28
PT836648E (pt)	2003-09-30
EP1312679B8 (en)	2005-11-23
SI0836648T1 (en)	2003-12-31
CZ292460B6 (cs)	2003-09-17
JP4764367B2 (ja)	2011-08-31
EP1312679A1 (en)	2003-05-21
ES2249648T3 (es)	2006-04-01
DE69628011D1 (de)	2003-06-12
UA75410C2 (en)	2006-04-17
BR9609303A (pt)	1999-05-25
IL164318A0 (en)	2005-12-18
US8153138B2 (en)	2012-04-10
JP4312260B2 (ja)	2009-08-12
US20100266630A1 (en)	2010-10-21
US20030035792A1 (en)	2003-02-20
TW575664B (en)	2004-02-11
BR9609303B1 (pt)	2014-04-08
HU224061B1 (hu)	2005-05-30
UA75411C2 (en)	2006-04-17
EE200300332A (et)	2003-10-15
EP0836648B1 (en)	2003-05-07
AU721735B2 (en)	2000-07-13
UA68327C2 (en)	2004-08-16
CN1782071A (zh)	2006-06-07
NZ313597A (en)	1999-01-28
RU2198217C2 (ru)	2003-02-10
US8197825B2 (en)	2012-06-12
DE69635172T2 (de)	2006-06-22
CN1189857A (zh)	1998-08-05
HK1068015A1 (en)	2005-04-22
HU0402350D0 (en)	2005-01-28
EP0836648A1 (en)	1998-04-22
NO980026D0 (no)	1998-01-02
CA2596274C (en)	2010-09-07
DK1312679T3 (da)	2006-01-09
CZ424197A3 (cs)	1998-03-18
IL122120A0 (en)	1998-04-05
EE05138B1 (et)	2009-02-16
HUP9802217A3 (en)	1999-09-28
CA2608864A1 (en)	1997-01-23
US20100291139A1 (en)	2010-11-18
DE69628011T2 (de)	2004-03-18
HK1009830A1 (en)	1999-06-11
US20070071769A1 (en)	2007-03-29
JP4764366B2 (ja)	2011-08-31
CA2596274A1 (en)	1997-01-23
EE9700344A (et)	1998-06-15
JPH11509091A (ja)	1999-08-17
JP2007252374A (ja)	2007-10-04
IL202448A0 (en)	2011-07-31
WO1997002355A1 (en)	1997-01-23
SI1312679T1 (sl)	2006-02-28
MX9800025A (es)	1998-03-31
CA2225278A1 (en)	1997-01-23
US20070071770A1 (en)	2007-03-29
CN1154742C (zh)	2004-06-23
PL186857B1 (pl)	2004-03-31
IL219528A0 (en)	2012-06-28
IL164318A (en)	2013-08-29
KR19990028617A (ko)	1999-04-15
CN1554764B (zh)	2012-03-21
PL324347A1 (en)	1998-05-25
NO980026L (no)	1998-01-02
NO322476B1 (no)	2006-10-09
US7198934B2 (en)	2007-04-03
DE69635172D1 (de)	2005-10-13
CA2608864C (en)	2010-09-07
DE69635173D1 (de)	2005-10-13
EE04753B1 (et)	2006-12-15
AU6611096A (en)	1997-02-05
EP1312679B1 (en)	2005-09-07
EE04199B1 (et)	2003-12-15

Legal Events

Date	Code	Title	Description
2017-02-11	MK4A	Expiration of patent term of an invention patent